A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To study the anti-HIV activity of the various doses of Ro 24-7429 monotherapy based on virologic and immunologic endpoints. To study the safety and tolerance of Ro 24-7429. To explore relationships between exposure to Ro 24-7429 and its metabolites and antiviral activity and drug toxicity. To determine a safe, tolerable, and active dose regimen of Ro 24-7429, and to make preliminary observations of Ro 24-7429 in combination with another antiretroviral nucleoside. The HIV genome contains a number of genes that regulate viral replication. Control of the activity of these genes and their encoded proteins represents a potential target for development of new antiretroviral drugs. The tat (transactivator of transcription of HIV) antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach for therapy of HIV infection.

Key facts

Study ID

NCT00000760

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

96

Last updated by the study team

2008-08-04

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Chemoprophylaxis for P. carinii pneumonia, TB, and mucocutaneous candidiasis.
• Methadone maintenance.
• Hormonal contraceptives.
• Patients must have:
• HIV-1 seropositivity.
• CD4 count 50 - 500 cells/mm3.
• Life expectancy of at least 24 weeks.
• Stable weight (+/- 2 kg) by 28 days prior to study entry (by history).
• NOTE:
• At least 50 percent of patients must be p24 antigen positive (>= 50 pg/ml).

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms and conditions are excluded:
• Known or suspected hypersensitivity to benzodiazepines.
• Presence of any malignancy other than basal cell carcinoma or limited cutaneous Kaposi's sarcoma (defined as no more than five lesions with no mucosal involvement).
• Ongoing diarrhea, defined as more than 2 liquid stools per day.
• History, physical exam, or laboratory results consistent with a subclinical AIDS-defining opportunistic infection.
• Grade 2 or greater signs and symptoms of AIDS Dementia Complex.
• Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal, endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease.
• Concurrent Medication:
• Excluded:
• Chronic suppressive therapy for CMV, MAI, toxoplasmosis, cryptococcosis, cryptosporidiosis, coccidioidomycosis, and histoplasmosis.
• ddC, ddI, AZT (except for control groups) or other experimental antiretrovirals or immunomodulating agents.
• Other medications excluded from the study.
• Patients with the following prior conditions are excluded:
• History of serious adverse reactions to benzodiazepines.
• History of intolerance to AZT at 600 mg/day or less or ddI at 400 mg/day or less.
• History of unexplained fever, defined as a temperature of 38.5 deg C or greater with or without night sweats for more than 7 of the past 28 days.
• Prior Medication:
• Excluded:
• Benzodiazepines within 14 days prior to study entry.
• Active drug or alcohol abuse that would interfere with study compliance.

Where it is running

• UCSD — San Diego, California, United States
• Johns Hopkins Hosp — Baltimore, Maryland, United States
• Harvard (Massachusetts Gen Hosp) — Boston, Massachusetts, United States
• Case Western Reserve Univ — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.